Copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Feb 14, 2023; 29(6): 967-996
Published online Feb 14, 2023. doi: 10.3748/wjg.v29.i6.967
Published online Feb 14, 2023. doi: 10.3748/wjg.v29.i6.967
Periodontal treatment and microbiome-targeted therapy in management of periodontitis-related nonalcoholic fatty liver disease with oral and gut dysbiosis
Ryutaro Kuraji, Department of Periodontology, The Nippon Dental University School of Life Dentistry at Tokyo, Tokyo 102-0071, Japan
Ryutaro Kuraji, Yvonne L Kapila, Department of Orofacial Sciences, University of California San Francisco, San Francisco, CA 94143, United States
Takahiko Shiba, Department of Oral Medicine, Infection, and Immunity, Harvard School of Dental Medicine, Boston, MA 02115, United States
Takahiko Shiba, Department of Periodontology, Tokyo Medical and Dental University, Tokyo 113-8549, Japan
Tien S Dong, The Vatche and Tamar Manoukian Division of Digestive Diseases, University of California Los Angeles, Department of Medicine, University of California David Geffen School of Medicine, Los Angeles, CA 90095, United States
Yukihiro Numabe, Department of Periodontology, The Nippon Dental University School of Life Dentistry at Tokyo, Tokyo 102-8159, Japan
Yvonne L Kapila, Sections of Biosystems and Function and Periodontics, Professor and Associate Dean of Research, Felix and Mildred Yip Endowed Chair in Dentistry, University of California Los Angeles, Los Angeles, CA 90095, United States
Author contributions: Kuraji R made significant contributions to the conception and design of the article as corresponding author. Kapila YL provided professional English language checking and proofreading throughout the manuscript. Kuraji R, Shiba T, Dong TS, Numabe Y, Kapila YL participated in literature review, retrieval, synthesis, and writing this paper, and approved the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ryutaro Kuraji, DDS, PhD, Associate Professor, Lecturer, Department of Periodontology, The Nippon Dental University School of Life Dentistry at Tokyo, 1-9-20, Fujimi, Chiyoda-ku, Tokyo 102-0071, Japan. r-kuraji@tky.ndu.ac.jp
Received: October 16, 2022
Peer-review started: October 16, 2022
First decision: November 3, 2022
Revised: November 14, 2022
Accepted: January 30, 2023
Article in press: January 30, 2023
Published online: February 14, 2023
Peer-review started: October 16, 2022
First decision: November 3, 2022
Revised: November 14, 2022
Accepted: January 30, 2023
Article in press: January 30, 2023
Published online: February 14, 2023
Core Tip
Core Tip: A growing body of evidence from multiple areas highlights that periodontal disease, accompanied by oral inflammation and pathological changes in the microbiome, induces gut dysbiosis and is involved in the pathogenesis of Nonalcoholic fatty liver disease (NAFLD). Thus, the conventional periodontal treatment and microbiome-targeted therapies that include probiotics, prebiotics and bacteriocin would hold great promise for preventing the onset and progression of NAFLD. In this review, we will describe the link between periodontal disease and NAFLD with a focus on basic, epidemiological, and clinical studies, and discuss potential mechanisms linking the two diseases and possible therapeutic approaches focused on the microbiome.